[MIK HOT SPOT_KHIDI] PDxen develops personalized cancer patient management platform… Three years of effort for technology and know-hows for cultivating cancer cells in blood finally pays off!

2020-05-07, Jane Lee Reporter

Although there are many studies on early-stage cancer, it is not easy to find a health care platform for cancer patients and a program to predict metastatic cancer. In this situation, Ahn Kwang-seong, CEO of PDxen, decided to start his own company to solve the lack of clinical tests. PDxen is researching the field of metastatic cancer based on cell biology.

The leading cause of death in cancer patients is metastatic cancer. Since the survival rate of cancer patients can be maximized when metastatic cancer is detected early, paradigm is changing from an early cancer diagnosis to an early metastatic cancer diagnosis for the treatment of cancer patients.

Real-time cell tracking system capable of analyzing biological characteristics of cancer cells in blood

Many researchers are continuing the research on predicting the recurrence and metastasis by the CTC (circulating tumor cell) analysis to find early-stage metastatic cancer not found by CT or MRI.  However, after chemotherapy, the discovery of cancer cells in the blood has limitations in predicting the recurrence and metastasis of cancer patients, and when a large number of cancer cells are found in the blood of cancer patients, the patients may already have metastatic cancer. Therefore, there is a limitation in predicting the recurrence and metastasis of cancer patients based on the analysis of the presence or absence of cancer cells in the blood.

It is reported that metastatic cancer is formed by recurrence and metastasis due to a combination of genetic factors and environmental factors, and that the microscopic long-term environment plays an important role. In addition, recurrent and metastatic cancers are generally observed to be refractory to anticancer drugs, so the anticancer treatment effect of cancer patients is very low, suggesting the cause of death due to metastatic cancer. Therefore, a new anticancer selection platform for metastatic cancer is being required.

Cancer organoid chip for anti-cancer drug sensitivity analysis of cancer cells in blood in a bio-like environment

After chemotherapy, people rely on CT and MRI every six months to get check ups to diagnose the recurrence and metastasis of cancer. By using PDgen's platform, people can predict the formation of micro-metastatic cancer early by the analysis on cancer cells in blood and clinical information every month, thus maximizing the survival rate of cancer patients by presenting the possibility of early treatment by selecting the target anti-cancer agents that target micro-metastatic cancer.

AI-based analysis algorithm for integrated analysis of genetic and environmental factors of cancer cells in blood

PDxen (CEO Ahn Kwang-seong) developed the medical device capable of predicting the presence of micrometastatic cancer that are not observed in CT or MRI based on the biological properties of cancer cells in blood and the analysis platform using cancer organoids that can have similar structure similar to a living environment by analyzing the sensitivity of cancer cells in blood to anticancer agent based on the genetic analysis of cancer cells in blood.

PDxen (CEO Ahn Kwang-seong) developed the medical device capable of predicting the presence of micrometastatic cancer that are not observed in CT or MRI based on the biological properties of cancer cells in blood and the analysis platform using cancer organoids that can have similar structure similar to a living environment by analyzing the sensitivity of cancer cells in blood to anticancer agent based on the genetic analysis of cancer cells in blood.

It is primarily sold as research equipment for the purpose of characterizing the biological properties of cancer cells in blood. For evaluating the clinical effectiveness by the analysis of the presence or absence of cancer cells in blood in a bio-like environment and developing the AI algorithm for the analysis of anti-cancer agent sensitivity in blood that can form micro-metastatic cancer, PCASI, developed by PDxen, is currently submitted for medical device registration to use it as a management platform for personalized cancer patients in clinical field.

The products and services of the major companies of KHIDI Health Industry Startup Innovation Center in the MIK Hot Spot (Made in Korea Online Exhibition) will also be displayed in BIO KOREA 2020. Asia's biggest bio convention BIO KOREA 2020 co-organized by KHIDI and Chungbuk Province and sponsored by MOHW will be open online due to the COVID-29 pandemic on May 18-23. Virtual exhibition halls, conference, and business forums will be operated, and the companies will be promoting their competitiveness. Also, with video meetings, businesses between overseas speakers, buyers, and domestic and foreign participating companies will be made. To date, more than 160 companies have applied for the virtual exhibition booth at BIO KOREA 2020. Companies wishing to participate can apply through the web page or email by Apr. 30.

The global news network AVING News has begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small and medium-sized companies enter the market and attract investment 365 days a year. AVING News has been running online exhibitions since 2005 and had 975 online exhibitions so far. Its YouTube online exhibition has placed itself as Korea's largest online exhibition hall that opens with 19,000 videos (booths) with more than 800,000 visits per month which means more than 10 million visits per year. The MIK Hot Spot online exhibition is scheduled to be held regularly according to the field, target market, and participating institutions, and it will be presented as a new type of online business by transforming the know-hows and values of the participating companies according to the trend. Companies that want to participate can apply and apply through the marketing support projects from supporting institutions in the local governments. Refer to the institutions for more information.

→ Go to MIK Hot Spot (Made in Korea Online Exhibition) special page

→ Go to MIK Hot Spot (Made in Korea Online Exhibition) information page

[ⓒ avingnews, Prohibition of reprinting and redistribution prohibited]